Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Invivyd, Inc. - Common Stock (NQ:IVVD)

2.265 +0.105 (+4.86%)
Streaming Delayed Price Updated: 3:23 PM EST, Dec 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Invivyd, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Invivyd to Participate at the 8th Annual Evercore Healthcare Conference
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Proposed Public Offering of Common Stock
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer
From Invivyd
Via GlobeNewswire
News headline image
SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd’s VYD2311 At RECOVER-TLC Workshop September 9-10, 2025
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Participate in Upcoming Investor Conferences
From Invivyd
Via GlobeNewswire
News headline image
Power Metallic’s (TSX-V: PNPN | OTCQB: PNPNF) Strategic Appointment Signals Major Paradigm Shift Ahead – More Stocks Inside
Via AB Newswire
Topics Government
News headline image
Invivyd Announces Closing of $57.5 Million Public Offering and Full Exercise of the Underwriter’s Option to Purchase Additional Shares
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Pricing of $50 Million Public Offering of Common Stock and Pre-Funded Warrants
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Proposed Public Offering of Common Stock
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Continued Neutralizing Activity of PEMGARDA® (pemivibart) and VYD2311 Against Currently Dominant SARS-CoV-2 Variant XFG (“Stratus”)
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19
From Invivyd
Via GlobeNewswire
News headline image
Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome
From Invivyd
Via GlobeNewswire
News headline image
National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2
From Invivyd
Via GlobeNewswire
News headline image
Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles
From Invivyd
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.